“Election to the academies of the Royal Society of Canada
is the highest honour a scholar can achieve in the Arts, Humanities and Sciences,” the Royal Society of Canada said in a Sept. 6 statement announcing its fellowship winners for 2013. The association notes that fellows are elected by their peers “in recognition of outstanding scholarly, scientific and artistic achievement.”
Hudlicky holds a Tier 1 Canada Research Chair in Organic Synthesis and Biocatalysis
(biological methods of manufacturing). His research focuses on new pain and cancer medicines, green chemistry and natural product synthesis. His breakthroughs in green chemistry include more efficient and environmentally conscious ways to create synthetic versions of morphine or Tamiflu-like drugs, earning him the reputation of being one of North America’s top organic researchers.
Ever since coming to Brock in 2003 from the University of Florida, Hudlicky has had a wide array of accomplishments. One of the most notable includes winning the highly coveted 2010 Alfred Bader Award, given by the Canadian Society of Chemistry for excellence in organic chemistry research.
Earlier this year, he won the Ontario Partnership for Innovation and Commercialization’s Innovator of the Year Award. This past spring, the Professor of Chemistry also passed the $1-million mark in revenues generated through licensing agreements for processes developed in his labs, mainly for the manufacture of important medicinal agents for pain control and alcohol and drug addiction.
“Dr. Hudlicky is an excellent example for how researchers in Canadian universities can impact and benefit our communities and our world,” says Gary Libben, Brock’s Vice-President of Research.